Improvement of sexual functioning during treatment of MDD with adjunctive pimavanserin: A secondary analysis
Sign Up to like & getrecommendations! Published in 2020 at "Depression and Anxiety"
DOI: 10.1002/da.23017
Abstract: Sexual dysfunction is common among patients with major depressive disorder (MDD). In the CLARITY study, the safety and efficacy of adjunctive pimavanserin, an inverse agonist at 5‐HT2A receptors, were demonstrated when added to existing treatment… read more here.
Keywords: analysis; adjunctive pimavanserin; treatment mdd;
Effect of adjunctive pimavanserin on suicidal ideation in patients with major depression: Analysis of the CLARITY study.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of affective disorders"
DOI: 10.1016/j.jad.2020.08.051
Abstract: BACKGROUND Up to 15% of patients with major depressive disorder (MDD) attempt suicide and up to 2% complete suicide. This was a post-hoc analysis aimed to evaluate the risk of suicide ideation and behavior associated… read more here.
Keywords: adjunctive pimavanserin; ideation; analysis; study ... See more keywords
Effects of adjunctive pimavanserin and current antipsychotic treatment on QT interval prolongation in patients with schizophrenia
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Psychiatry"
DOI: 10.3389/fpsyt.2022.892199
Abstract: Background Pimavanserin prolongs the QT interval, with mean increases in corrected QT (QTc) of 5–8 ms, and is currently being investigated for the treatment of negative symptoms of schizophrenia. Objectives To assess QT interval prolongation… read more here.
Keywords: prolongation; antipsychotic treatment; postbaseline; adjunctive pimavanserin ... See more keywords